Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Thera (NQ: VKTX )

53.45 +0.03 (+0.06%)
Streaming Delayed Price Updated: 11:13 AM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Thera

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review
The major indexes were mixed for the week. 
Via Investor's Business Daily
Why Viking Therapeutics Stock Soared by Nearly 21% on Thursday
The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug. 
Via The Motley Fool
3 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday
Via Benzinga
An Overview of Viking Therapeutics's Earnings
Via Benzinga
Market Whales and Their Recent Bets on VKTX Options
Via Benzinga
How Viking Therapeutics Just Dealt A Blow To Eli Lilly's Obesity Triplet
Viking is planning to file with the FDA next year to begin testing a quadruple approach to weight loss. 
Via Investor's Business Daily
Exposures Product Safety
3 Growth Stocks That Have Generated 1,000% Returns Since the Last Presidential Election (and They've All Outperformed Nvidia)
Regardless of who wins the presidency, investors are better off focusing on top growth stocks. 
Via The Motley Fool
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition. 
Via Benzinga
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
Viking Therapeutics (VKTX) set to report Q3 earnings amid high expectations, thanks to promising weight-loss drug candidate. Stock up 240% YTD. 
Via Benzinga
Viking Therapeutics Gives Investors Another Reason to Remain Bullish on Its Future
Viking recently announced the results of an early-stage clinical trial for VK0214. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years
Via Benzinga
Viking Therapeutics Unusual Options Activity
Via Benzinga
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
The analyst is closely watching MariTide, a potential monthly injection to treat obesity. 
Via Investor's Business Daily
Where Will Viking Therapeutics Be in 5 Years?
We could be witnessing the birth of a major player in the biotech industry. 
Via The Motley Fool
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
It's hard to go wrong with either company, but one is more appealing. 
Via The Motley Fool
The Ultimate Biotech Stock to Buy With $100 Right Now
This company is operating in one of today's hottest markets. 
Via The Motley Fool
Viking Therapeutics Unusual Options Activity For September 24
Via Benzinga
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns. 
Via Benzinga
Viking Therapeutics Reveals Encouraging Data From Genetic Disorder Drug Study, Analyst Says Focus On Orphan Disease Broadens Viking's Potential Revenue Streams
Viking Therapeutics' VK0214 Phase 1b trial in X-ALD patients showed significant reductions in VLCFAs and other lipids, while demonstrating safety. Analyst sees potential revenue upside with continued... 
Via Benzinga
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
The investment bank analysts who follow these stocks think they can soar even further, with some caveats. 
Via The Motley Fool
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention. 
Via Investor's Business Daily
Why Viking Therapeutics Stock Topped the Market Today
An analyst waxed bullish on the company's leading pipeline program. 
Via The Motley Fool
Is Viking Therapeutics Stock a Buy?
The company is in the spotlight for one of its programs, but it's got others that also have promise. 
Via The Motley Fool
Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics
One of them is performing much better than the other this year. 
Via The Motley Fool
Is Viking Therapeutics Ready For Another Surge?
Viking Therapeutics' promising weight loss drug could revolutionize the obesity market and propel the company's stock price to new highs. 
Via MarketBeat
Why Viking Therapeutics Stock Was So Healthy on Wednesday
Hardly for the first time, a pundit following the company waxed bullish on its future. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.